
ADC Therapeutics (ADCT) Stock Forecast & Price Target
ADC Therapeutics (ADCT) Analyst Ratings
Bulls say
ADC Therapeutics SA, a biotechnology company focused on developing antibody-drug conjugates for oncology treatments, is poised for significant revenue growth driven by its marketed product ZYNLONTA, which is currently experiencing annual sales of approximately $70 million in its approved indication. The company's conservative modeling indicates that the third-line treatment opportunity could expand, potentially increasing revenues by about $170 million and raising peak revenue estimates for ZYNLONTA to $629.1 million by 2032, significantly up from previous estimates. With the anticipated expansion of ZYNLONTA into second-line treatment and strong activity indicators in emerging markets, ADC Therapeutics is positioned for notable growth in the coming years, reflecting positively on its financial prospects.
Bears say
ADC Therapeutics faces significant challenges that contribute to a negative outlook on its stock performance. The company's reliance on third-party contract manufacturing organizations (CMOs) poses a risk of operational bottlenecks that could delay clinical trials and commercialization efforts, affecting its ability to generate revenue. Additionally, the potential for unfavorable clinical trial data related to its various product candidates and ongoing safety concerns could jeopardize the development pipeline, further complicating the pathway to achieving profitability and cash flow generation.
This aggregate rating is based on analysts' research of ADC Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
ADC Therapeutics (ADCT) Analyst Forecast & Price Prediction
Start investing in ADC Therapeutics (ADCT)
Order type
Buy in
Order amount
Est. shares
0 shares